{"id":2274,"date":"2023-01-24T19:24:50","date_gmt":"2023-01-25T01:24:50","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=2274"},"modified":"2023-01-24T19:24:53","modified_gmt":"2023-01-25T01:24:53","slug":"how-effective-is-nirmatrelvir-ritonavir-in-vaccinated-persons-with-covid-19","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2023\/01\/24\/how-effective-is-nirmatrelvir-ritonavir-in-vaccinated-persons-with-covid-19\/","title":{"rendered":"How Effective Is Nirmatrelvir\/Ritonavir in Vaccinated Persons with COVID-19?"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p>(<a href=\"https:\/\/www.jwatch.org\/na55626\/2023\/01\/24\/how-effective-nirmatrelvir-ritonavir-vaccinated-persons\">NEJM<\/a>) Preferred therapies for mild-to-moderate COVID-19 include a 3-day intravenous course of remdesivir or nirmatrelvir\/ritonavir (Paxlovid). The only published randomized trial of nirmatrelvir\/ritonavir was conducted prior to widespread vaccination (<a rel=\"noreferrer noopener\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa2118542\" target=\"_blank\">N Engl J Med 2022; 386:1397. opens in new tab<\/a>). Thus, clinicians need further information on the effectiveness of this treatment in more-heavily immune populations. Investigators conducted a retrospective cohort study involving 44,551 patients aged \u226550 (of whom 90% had received at least 3 doses of vaccine) eligible to receive nirmatrelvir\/ritonavir. The 28% of patients who received nirmatrelvir\/ritonavir had more comorbidities and were more likely to be vaccinated. Black and Hispanic patients \u2014 but not patients from disadvantaged neighborhoods \u2014 were less likely to receive nirmatrelvir\/ritonavir. Hospitalization or death within 28 days of diagnosis occurred in 69 treated patients (0.55%) and 310 untreated patients (0.97%). Adjusted risk ratios for hospitalization (0.60) and death (0.29) favored treatment, particularly in those who were unvaccinated or were >20 weeks from their last immunization. No difference in relative benefit was observed between patients older or younger than 65.<\/p>\n<div style=\"display: none;\"><a rel=\"nofollow\" href=\"\/secure-location.php\" title=\"k Gt y J  bB \">k Gt y J  bB <\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>(NEJM) Preferred therapies for mild-to-moderate COVID-19 include a 3-day intravenous course of remdesivir or nirmatrelvir\/ritonavir (Paxlovid). The only published randomized trial of nirmatrelvir\/ritonavir was conducted prior to widespread vaccination (N Engl J Med 2022; 386:1397. opens in new tab). Thus, clinicians need further information on the effectiveness of this treatment in more-heavily immune populations. Investigators [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[35,14],"tags":[],"class_list":["post-2274","post","type-post","status-publish","format-standard","hentry","category-covid-therapies","category-science-and-tech"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/2274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=2274"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/2274\/revisions"}],"predecessor-version":[{"id":2275,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/2274\/revisions\/2275"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=2274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=2274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=2274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}